Pharmaceutical company Cassiopea SpA (SIX:SKIN) said on Tuesday that it has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) seeking marketing approval for clascoterone cream 1% for the treatment of the dermatological condition acne.
Under investigation as a first-in-class topical androgen receptor inhibitor for treating acne, the clascoterone cream 1% is a topically delivered small molecule that penetrates the skin to reach the androgen receptors of the sebaceous gland. The clascoterone inhibits lipid production from oil producing cells and reduces proinflammatory cytokines, mediators influenced by androgens, added the company.
Unlike oral hormonal therapies for acne, the clascoterone cream 1% may be used in both male and female patients and is also the first new mechanism of action for acne in nearly 40 years, according to the company.
Based on the topline results from two pivotal phase III clinical trials for clascoterone cream 1%, the candidate demonstrated highly statistically significant improvements for all primary clinical endpoints. The safety results were confirmed in an open-label safety study for a treatment period of up to one year, with an expanded drug application surface area that included both the face and trunk.
In addition, clascoterone is on track to becoming the first effective and safe topical anti-androgen without systemic side effects, concluded the company.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study